The real-life early and continuative response to Galcanezumab in chronic migraine: 3-month analysis of the multicenter prospective cohort GARLIT study

被引：0

作者：

Altamura, C. ^{[1
]}

Brunelli, N. ^{[1
]}

Costa, C. M. ^{[1
]}

Aurilia, C. ^{[2
]}

Egeo, G. ^{[2
]}

Fofi, L. ^{[2
]}

Favoni, V. ^{[3
]}

Pierangeli, G. ^{[3
]}

Messina, R. ^{[4
]}

Filippi, M. ^{[4
]}

Colombo, B. ^{[4
]}

Lovati, C. ^{[5
]}

Aguggia, M. ^{[6
]}

Bertuzzo, D. ^{[6
]}

D'Onofrio, F. ^{[7
]}

Doretti, A. ^{[8
,9
]}

Di Fiore, P. ^{[10
]}

Frediani, F. ^{[10
]}

Finocchi, C. ^{[11
]}

Rao, R. ^{[12
]}

Di Cola, F. Schiano

Bono, F. ^{[13
]}

Ranieri, A. ^{[14
]}

Albanese, M. ^{[15
]}

Cevoli, S. ^{[3
]}

Barbanti, P. ^{[2
]}

Vernieri, F. ^{[1
]}

机构：

[1] Campus Biomed Univ Rome, Neurol, Rome, Italy

[2] IRCCS San Raffaele Pisana, Headache & Pain Unit, Rome, Italy

[3] IRCCS Ist Sci Neurol Bologna, Bologna, Italy

[4] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy

[5] Univ Hosp L Sacco, Neurol Unit, Milan, Italy

[6] Asti Hosp, Neurol & Stroke Unit, Asti, Italy

[7] Giuseppe Moscati Hosp, Neurol Unit, Avellino, Italy

[8] IRCCS, Ist Auxol Italiano, Stroke Unit, Neurol, Milan, Italy

[9] Lab Neurosci, Milan, Italy

[10] San Carlo Borromeo Hosp, ASST Santi Paolo & Carlo Milan, Headache Ctr, Neurol & Stroke Unit, Milan, Italy

[11] Osped Policlin San Martino, IRCCS, Genoa, Italy

[12] Univ Brescia, Dept Clin & Expt Sci, Neurol Unit, Brescia, Italy

[13] AOU Mater Domini, Neurol Unit, Catanzaro, Italy

[14] A Cardarelli Hosp, Headache Ctr, Neurol & Stroke Unit, Naples, Italy

[15] Univ Hosp Rome Tor Vergata, Dept Syst Med, Rome, Italy

来源：

JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P0343

引用

页码：123 / 123

页数：1

共 50 条

[31] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: FRIEND (FRemanezumab In rEal world stuDy), the first Italian multicenter, prospective real-life study
Fofi, L.
Egeo, G.
Aurilia, C.
Costa, C. M.
Altamura, C.
Vernieri, F.
Albanese, M.
D'Onofrio, F.
Di Clemente, L.
Zucco, M.
Di Fiore, P.
Frediani, F.
Messina, R.
Colombo, B.
Filippi, M.
Bono, F.
Manzo, L.
Carnevale, A.
Barbanti, P.
Proietti, S.
Bonassi, S.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 171 - 172
[32] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study
Fofi, Luisa
Egeo, Gabriella
Aurilia, Cinzia
Costa, Carmelina
Altamura, Claudia
Vernieri, Fabrizio
Albanese, Maria
D'Onofrio, Florindo
Di Clemente, Laura
Zucco, Maurizio
Di Fiore, Paola
Frediani, Fabio
Messina, Roberta
Colombo, Bruno
Filippi, Massimo
Bono, Francesco
Manzo, Lucia
Carnevale, Antonio
Barbanti, Piero
Proietti, Stefania
Bonassi, Stefano
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 204 - 204
[33] Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 24-week, multicenter, real-life, cohort study (the FRIEND study)
Egeo, Gabriella
Aurilia, Cinzia
Torelli, Paola
d'Onofrio, Florindo
Laura, Di Clemente
Finocchi, Cinzia
Di Fiore, Paola
Sette, Giuliano
Vernieri, Fabrizio
Grazzi, Licia
Le Pera, Domenica
Valenza, Alessandro
Albanese, Maria
Viticchi, Giovanna
Proietti, Stefania
Bonassi, Stefano
Barbanti, Piero
CEPHALALGIA, 2022, 42 (1_SUPPL) : 100 - 101
[34] The First, Italian, Multicenter, Real-life Study with Erenumab in the Prevention of High Frequency Episodic and Chronic Migraine
Barbanti, Piero
Aurilia, Cinzia
Cevoli, Sabina
Colombo, Bruno
Frediani, Fabio
Bono, Francesco
Grazzi, Licia
D'Amico, Domenico
Salerno, Antonio
Mercuri, Bruno
Carnevale, Antonio
Vollono, Catello
Egeo, Gabriella
Fofi, Luisa
Altamura, Claudia
Costa, Carmen
Brunelli, Nicoletta
Fallacara, Adriana
Pierangeli, Giulia
Favoni, Valentina
Messina, Roberta
Filippi, Massimo
Di Fiore, Paola
Santangelo, Domenico
Vernieri, Fabrizio
NEUROLOGY, 2020, 94 (15)
[35] Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study
Yavropoulou, Maria P.
Filippa, Maria G.
Vlachogiannis, Nikolaos, I
Fragoulis, George E.
Laskari, Katerina
Mantzou, Aimilia
Panopoulos, Stylianos
Fanouriakis, Antonis
Bournia, Vasiliki-Kalliopi
Evangelatos, Gerasimos
Papapanagiotou, Aggeliki
Tektonidou, Maria G.
Chrousos, George P.
Sfikakis, Petros P.
RMD OPEN, 2024, 10 (01):
[36] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
Detke, Holland C.
Wang, Shufang
Skljarevski, Vladimir
Ahl, Jonna
Millen, Brian A.
Aurora, Sheena K.
Yang, Jyun Yan
CEPHALALGIA, 2017, 37 : 338 - 338
[37] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
Detke, H. C.
Wang, S.
Skljarevski, V
Ahl, J.
Millen, B.
Aurora, S. K.
Yang, J.
HEADACHE, 2017, 57 (08): : 1336 - 1337
[38] Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
Altamura, Claudia
Brunelli, Nicoletta
Viticchi, Giovanna
Salvemini, Sergio
Cecchi, Gianluca
Marcosano, Marilena
Fofi, Luisa
Silvestrini, Mauro
Vernieri, Fabrizio
TOXINS, 2023, 15 (04)
[39] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
Detke, Holland C.
Wang, Shufang
Skljarevski, Vladimir
Ahl, Jonna
Millen, Brian A.
Aurora, Sheena K.
Yang, Jyun Yan
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[40] Switching to Vortioxetine in Patients with Poorly Tolerated Antidepressant-Related Sexual Dysfunction in Clinical Practice: A 3-Month Prospective Real-Life Study
Montejo, Angel L.
Sanchez-Sanchez, Froilan
De Alarcon, Ruben
Matias, Juan
Cortes, Benjamin
Matos, Claudia
Martin-Pinto, Tomas
Rios, Penitas
Gonzalez-Garcia, Nerea
Acosta, Jose Maria
Adan, Ana
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)

← 1 2 3 4 5 →